Zymeworks Statistics
Total Valuation
Zymeworks has a market cap or net worth of $1.85 billion. The enterprise value is $1.47 billion.
Important Dates
The last earnings date was Thursday, May 7, 2026, after market close.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Zymeworks has 73.02 million shares outstanding. The number of shares has decreased by -0.41% in one year.
| Current Share Class | 73.02M |
| Shares Outstanding | 73.02M |
| Shares Change (YoY) | -0.41% |
| Shares Change (QoQ) | -0.85% |
| Owned by Insiders (%) | 1.31% |
| Owned by Institutions (%) | 48.79% |
| Float | 68.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 15.10 |
| PS Ratio | 22.82 |
| Forward PS | n/a |
| PB Ratio | 11.59 |
| P/TBV Ratio | 12.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 18.06 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.82, with a Debt / Equity ratio of 0.10.
| Current Ratio | 10.82 |
| Quick Ratio | 10.36 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -55.21 |
Financial Efficiency
Return on equity (ROE) is -42.02% and return on invested capital (ROIC) is -97.68%.
| Return on Equity (ROE) | -42.02% |
| Return on Assets (ROA) | -15.78% |
| Return on Invested Capital (ROIC) | -97.68% |
| Return on Capital Employed (ROCE) | -25.77% |
| Weighted Average Cost of Capital (WACC) | 10.81% |
| Revenue Per Employee | $334,416 |
| Profits Per Employee | -$422,453 |
| Employee Count | 243 |
| Asset Turnover | 0.18 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.31M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +120.10% in the last 52 weeks. The beta is 1.19, so Zymeworks's price volatility has been higher than the market average.
| Beta (5Y) | 1.19 |
| 52-Week Price Change | +120.10% |
| 50-Day Moving Average | 25.77 |
| 200-Day Moving Average | 21.99 |
| Relative Strength Index (RSI) | 48.97 |
| Average Volume (20 Days) | 660,303 |
Short Selling Information
The latest short interest is 4.65 million, so 6.37% of the outstanding shares have been sold short.
| Short Interest | 4.65M |
| Short Previous Month | 4.65M |
| Short % of Shares Out | 6.37% |
| Short % of Float | 6.83% |
| Short Ratio (days to cover) | 7.62 |
Income Statement
In the last 12 months, Zymeworks had revenue of $81.26 million and -$102.66 million in losses. Loss per share was -$1.36.
| Revenue | 81.26M |
| Gross Profit | -54.46M |
| Operating Income | -114.05M |
| Pretax Income | -103.97M |
| Net Income | -102.66M |
| EBITDA | -107.79M |
| EBIT | -114.05M |
| Loss Per Share | -$1.36 |
Full Income StatementBalance Sheet
The company has $364.73 million in cash and $17.04 million in debt, with a net cash position of $386.80 million or $5.30 per share.
| Cash & Cash Equivalents | 364.73M |
| Total Debt | 17.04M |
| Net Cash | 386.80M |
| Net Cash Per Share | $5.30 |
| Equity (Book Value) | 163.59M |
| Book Value Per Share | 2.19 |
| Working Capital | 350.03M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$75.32 million and capital expenditures -$1.72 million, giving a free cash flow of -$77.04 million.
| Operating Cash Flow | -75.32M |
| Capital Expenditures | -1.72M |
| Depreciation & Amortization | 6.27M |
| Net Borrowing | n/a |
| Free Cash Flow | -77.04M |
| FCF Per Share | -$1.05 |
Full Cash Flow StatementMargins
Gross margin is -67.01%, with operating and profit margins of -140.35% and -126.33%.
| Gross Margin | -67.01% |
| Operating Margin | -140.35% |
| Pretax Margin | -127.94% |
| Profit Margin | -126.33% |
| EBITDA Margin | -132.64% |
| EBIT Margin | -140.35% |
| FCF Margin | n/a |
Dividends & Yields
Zymeworks does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.41% |
| Shareholder Yield | 0.41% |
| Earnings Yield | -5.53% |
| FCF Yield | -4.15% |
Analyst Forecast
The average price target for Zymeworks is $40.15, which is 58.07% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $40.15 |
| Price Target Difference | 58.07% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (5Y) | 24.78% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zymeworks has an Altman Z-Score of -0.36 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.36 |
| Piotroski F-Score | 2 |
